Tag: Bayer

reduced hospital time and costs Xarelto anticoagulant

Real-world analysis confirms benefit of Xarelto in treating CAT as apixaban

Head-to-head observational analysis showed Xarelto as effective in treating cancer-associated thromboembolism (CAT) as apixaban. The Janssen Pharmaceutical Companies of Johnson & Johnson have announced observational...
reduced hospital time and costs Xarelto anticoagulant

Bayer receives approval in the UK for Xarelto to treat and...

Bayer has received approval in the UK for the use of its oral Factor Xa inhibitor Xarelto (rivaroxaban) to treat venous thromboembolism (VTE) and...